Celldex Therapeutics reported $20.98M in Operating Expenses for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Abbvie ABBV:US $ 10036M 518M
Amgen AMGN:US $ 4.33B 1.37B
Applied Genetic Technologies AGTC:US $ 16.42M 2.14M
Aptinyx Inc APTX:US $ 21.21M 1.34M
Arena Pharmaceuticals ARNA:US $ 194.48M 50.09M
Biocept BIOC:US $ 16.97M 3.17M
Bristol Myers Squibb BMY:US $ 9.63B 360M
Celldex Therapeutics CLDX:US $ 20.98M 4.06M
Cytrx CYTR:US 1.53M 351.4K
Glaxosmithkline GSK:US 7.14B 722M
Immunogen IMGN:US $ 43.44M 873K
Merrimack Pharmaceuticals MACK:US $ 886K 121K
Nektar Therapeutics NKTR:US $ 138.52M 18K
Newlink Genetics NLNK:US 7.5M 1.18M
Northwest Biotherapeutics NWBO:US 10.4M 2.56M
Pfizer PFE:US $ 16447M 3384M
Rigel Pharmaceuticals RIGL:US $ 41.33M 2.01M
Seattle Genetics SGEN:US $ 722.02M 243.94M